MAZE THERAPEUTICS, INC. Diluted Shares Outstanding (Weighted Average)
MAZE THERAPEUTICS, INC. (MAZE) reported Diluted Shares Outstanding (Weighted Average) of 59.00 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-11
- MAZE THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 59.00M shares, a 34.70% increase year-over-year.
- MAZE THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 53.90M shares, a 88.26% increase year-over-year.
- MAZE THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 53.51M shares, a 6943.61% increase year-over-year.
- MAZE THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 45.78M shares, a 1794.93% increase year-over-year.
- MAZE THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2025 was 42.98M shares, a 1474.04% increase from fiscal 2024.
- MAZE THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2024 was 2.73M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 59.00M shares 10-Q · filed 2026-08-11 | 56.46M shares 10-Q · filed 2026-08-11 | 55.47M shares derived: average of 3 quarters · filed 2026-08-11 | 53.05M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 53.90M shares 10-Q · filed 2026-05-12 | 53.70M shares derived: average of 2 quarters · filed 2026-05-12 | 51.06M shares derived: average of 3 quarters · filed 2026-05-12 | 49.25M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 53.51M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 49.64M shares derived: average of 2 quarters · filed 2026-03-25 | 47.70M shares derived: average of 3 quarters · filed 2026-08-11 | 42.98M shares 10-K · filed 2026-03-25 |
| 2025-09-30 | 45.78M shares 10-Q · filed 2025-11-06 | 44.79M shares derived: average of 2 quarters · filed 2026-08-11 | 39.46M shares 10-Q · filed 2025-11-06 | 29.74M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 43.80M shares 10-Q · filed 2026-08-11 | 36.25M shares 10-Q · filed 2026-08-11 | 24.40M shares derived: average of 3 quarters · filed 2026-08-11 | 18.90M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 28.63M shares 10-Q · filed 2026-05-12 | 14.69M shares derived: average of 2 quarters · filed 2026-05-12 | 10.60M shares derived: average of 3 quarters · filed 2026-05-12 | 9.03M shares derived: average of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | 759.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | 1.59M shares derived: average of 2 quarters · filed 2026-03-25 | 2.50M shares derived: average of 3 quarters · filed 2026-03-25 | 2.73M shares 10-K · filed 2026-03-25 |
| 2024-09-30 | 2.42M shares 10-Q · filed 2025-11-06 | 3.37M shares derived: average of 2 quarters · filed 2025-11-06 | 3.39M shares 10-Q · filed 2025-11-06 | |
| 2024-06-30 | 4.31M shares 10-Q · filed 2025-08-12 | 3.27M shares 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | 2.34M shares 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |